, Volume 79, Issue 17, pp 1905–1909 | Cite as

Trifarotene: First Approval

  • Lesley J. ScottEmail author
AdisInsight Report


Topical trifarotene (Aklief®) is a first-in-class, fourth-generation retinoid [selective retinoic acid receptor (RAR)-γ agonist] being developed by Galderma Research and Development LLC for the treatment of acne vulgaris. In October 2019 trifarotene received its first global approval in the USA for the topical treatment of acne vulgaris in patients 9 years of age and older. This article summarizes the milestones in the development of trifarotene leading to its first global approval for acne vulgaris.


Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflicts of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Lesley Scott is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    Chien AL. Retinoids in acne management: review of current understanding, future considerations, and focus on topical treatments. J Drugs Dermatol. 2018;17(12 Suppl):s51–5.PubMedGoogle Scholar
  2. 2.
    Kolli SS, Pecone D, Pona A, et al. Topical retinoids in acne vulgaris: a systematic review. Am J Clin Dermatol. 2019;20(3):345–65.CrossRefGoogle Scholar
  3. 3.
    US National Institue of Health. Lamellar ichthyosis. 2019. Accessed 15 Oct 2019.
  4. 4.
    Vahlquist A, Fischer J, Törmä H. Inherited nonsyndromic ichthyoses: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2018;19(1):51–66.CrossRefGoogle Scholar
  5. 5.
    FDA. Novel drug approvals for 2019. 2019. Accessed 15 Oct 2019.
  6. 6.
    Galderma. Aklief® (Trifarotene): US Prescribing Information. 2019. Accessed 2019 Oct 8.
  7. 7.
    Galderma. Galderma trifarotene development program meets key milestone for lamellar ichthyosis orphan disease [media release]. 2016. Accessed 15 Oct 2019.
  8. 8.
    Aubert J, Piwnica D, Bertino B, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-gamma agonist trifarotene. Br J Dermatol. 2018;179(2):442–56.PubMedGoogle Scholar
  9. 9.
    Thoreau E, Arlabosse J, Bouix-Peter C, et al. Structure-based design of trifarotene, a potent and selective RAR agonist for the treatment of acne. Bioorg Med Chem Lett. 2018;128(101736-41).Google Scholar
  10. 10.
    Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691–9.CrossRefGoogle Scholar
  11. 11.
    Blume-Peytavi U, Fowler J, Kemény L, et al. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2019. Scholar
  12. 12.
    Galderma (2019) Data on fileGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations